Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Age-dependent differences in first-line chemotherapy in patients with metastatic colorectal cancer: the DISCO study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Circulating tumour DNA alterations as biomarkers for head and neck cancer: a systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Incidence and malignant transformation of glottic precursor lesions in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Difficult journeys in sarcoma care; socioeconomic disparity added to the multiple challenges of a rare tumor diagnosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Long-term exposure to air pollution and stroke incidence: A Danish Nurse cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prognostic impact of Charlson's Age-Comorbidity Index and other risk factors in patients with pancreatic cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Systemic Immune Modulation in Gliomas: Prognostic Value of Plasma IL-6, YKL-40, and Genetic Variation in YKL-40

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVES: First-line chemotherapy for metastatic colorectal cancer (mCRC) is effective and feasible in selected older patients. We investigated age-dependent differences in treatment and outcomes in patients with mCRC in clinical practice.

MATERIAL AND METHODS: A retrospective study of 654 patients with mCRC referred to first-line chemotherapy in 2008-2014. Patients were divided into two age groups: 50-69 and ≥70 (older patients). Binary outcomes were analyzed by logistic regression. Progression-free survival (PFS) and overall survival (OS) were analyzed by Cox proportional hazards regression, CRC-specific and other-cause mortality with Fine and Gray proportional hazard model for the sub-distribution of a competing risk.

RESULTS: After adjusting for performance status (PS) and comorbidity, older patients were more likely to receive monotherapy (adjusted odds ratio (aOR) = 9.00, 95% confidence interval (CI) 4.52-17.91), lower doses, and no additional targeted therapy (aOR = 1.89, 95% CI 1.28-2.78) than younger patients. Yet, older patients experienced more toxicity and hospitalizations (aOR = 1.53, 95% CI 1.08-2.17). Among those treated, older patients had shorter PFS (hazard ratio (HR) = 1.32, 95% CI 1.11-1.57), but after adjusting for PS and comorbidity, PFS was similar. No significant difference was found in CRC mortality (HR = 1.15, 95% CI 0.95-1.40) between age groups. Poor PS was associated with shorter OS and PFS and higher CRC mortality.

CONCLUSIONS: In the DISCO study, older patients with mCRC received less aggressive first-line chemotherapy. Yet, they experienced more toxicity. Younger and older patients had similar CRC mortality. Shorter PFS and higher CRC mortality were observed in patients with poor PS.

OriginalsprogEngelsk
TidsskriftActa oncologica
Vol/bind57
Udgave nummer11
Sider (fra-til)1445-1454
Antal sider10
ISSN0284-186X
DOI
StatusUdgivet - nov. 2018

ID: 56443756